AptarGroup, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stephan Tanda
- Full Time Employees
- 14,000
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 265 Exchange Drive Crystal Lake IL United States of America 60014
- IPO Date
- Apr 23, 1993
- CIK
- 0000896622
- Website
- aptar.com
- Similar Companies
- Business
- AptarGroup, Inc. designs, manufactures and markets a broad range of drug delivery systems, consumer product dispensing systems, active material science solutions and sealing, packaging services for the pharmaceutical, beauty, personal care, home care, food and beverage industries worldwide. The company operates through three main segments: Aptar Pharma, which provides nasal and pulmonary drug delivery devices including pumps for nasal allergy treatments, metered-dose inhaler valves for respiratory conditions such as asthma and chronic obstructive pulmonary disease, elastomers for injectable packaging components, proprietary Unidose and Bidose intranasal delivery systems, aerosol valves, digital health solutions and clinical trial materials manufacturing services; Aptar Beauty, which offers dispensing pumps, closures, pouch spouts, spray pumps and valves for fragrance, make-up, skincare and cleansing products; and Aptar Closures, which supplies dispensing closures, dosing cups, droppers and other packaging solutions. AptarGroup sells its products primarily in North America, Europe, Asia and Latin America; the company was incorporated in 1992 and maintains headquarters in Crystal Lake, Illinois, with manufacturing facilities and over 13,000 employees across 20 countries. Recently, Aptar Pharma acquired the device technology assets of SipNose Nasal Delivery Systems in November 2025 to expand its intranasal drug delivery portfolio for local, systemic and central nervous system indications including nose-to-brain pathways; acquired clinical trial materials manufacturing capabilities of Mod3 Pharma in July 2025 to enhance Phase 1 and 2 formulation, fill-finish services for orally inhaled and nasal drug products at an FDA-inspected facility in Boonton, New Jersey; acquired Brazilian pharmaceutical packaging firm Sommaplast in December 2025 to strengthen oral dosing solutions such as closures, droppers, dispensers and dosing cups amid growth in over-the-counter and nutraceutical markets; issued approximately $600 million in senior unsecured notes due 2031 in November 2025 to bolster financial flexibility for operations and acquisitions; and extended collaboration with Nasus Pharma on intranasal epinephrine devices.
Chicago Partners Investment Group LLC Invests $505,000 in AptarGroup, Inc. $ATR
Aptar Declares Quarterly Dividend
Will AptarGroup (ATR) Beat Estimates Again in Its Next Earnings Report?
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
Aptar Releases 2025 Corporate Sustainability Report
AptarGroup, Inc. (ATR) Presents at 16th Annual Wells Fargo Industrials & Materials Conference Transcript
A Look at AptarGroup Inc (ATR) After 3.5% Gain -- GF Value $156.52 vs Price $115.90
AptarGroup, Inc. (ATR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Aptar Named a CDP Supplier Engagement Leader for the Sixth Consecutive Year
Aptar to Participate in Upcoming Investor Conferences
AptarGroup Sets CEO Succession as 2025 Sales Rise and Shareholders Back Ballot
AptarGroup Q1 Earnings Beat Estimates but Decline Y/Y, Shares Dip 1%
Advanced Technology Recycling (ATR) Announces That They Are Now Offering Wholesale Electronics to the General Public Through Their Online Auction Site
Is AptarGroup Inc (ATR) a Bargain After 3.8% Drop? GF Value Says Undervalued
AptarGroup, Inc. (ATR) Q1 2026 Earnings Call Transcript
AptarGroup (ATR) Beats Q1 Earnings and Revenue Estimates
Aptar Reports First Quarter 2026 Results
Avery Dennison Q1 Earnings Top Estimates on Volume Gains, Cost Control
Analysts Estimate Graphic Packaging (GPK) to Report a Decline in Earnings: What to Look Out for
Avery Dennison (AVY) Q1 Earnings and Revenues Surpass Estimates